

Evaluation Report for Category B, Subcategory 1.1 Application

Application Number: 2023-0153
Application: Changes to a Technical Grade Active Ingredient (Product Chemistry) – New Source (Site) Same Registrant
Product: HF Glufosinate-Ammonium 98%
Registration Number: 33487
Active ingredient (a.i.): Glufosinate-ammonium
PMRA Document Number : 3627289

Purpose of Application

The purpose of this application was to register two new sources of glufosinate-ammonium for HF Glufosinate-Ammonium 98%

Chemistry Assessment

Common Name: glufosinate-ammonium
 IUPAC* Chemical Name: ammonium [(3*RS*)-3-amino-3-carboxypropyl]methylphosphinate
 CAS† Chemical Name: 2-amino-4-(hydroxymethylphosphinyl)butanoic acid monoammonium salt

* International Union of Pure and Applied Chemistry

† Chemical Abstracts Service

HF Glufosinate-Ammonium 98% has the following properties:

Property	Result
Colour and physical state	White, solid
Nominal concentration	98%
Odour	Odourless
Density	1.39 g/mL at 20°C
Vapour pressure	0.00224 mPa at 20°C
pH	4.39
Solubility in water	9.89 × 10 ⁵ mg/L (pH 4.5)
n-Octanol/water partition coefficient	log K _{ow} < -1.37

The required chemistry data for HF Glufosinate-Ammonium 98% have been provided, reviewed, and found to be acceptable.

Health, Environmental and Value Assessments

Health, environmental and value assessments were not required for this application.

Conclusion

The Pest Management Regulatory Agency has completed an assessment of the information provided, and has found the information acceptable to support the registration of two new sources for HF Glufosinate-Ammonium 98%.

References

PMRA

Document

Number	Reference
2907732	2015, update chemical and physical properties report, DACO: 2.14
3425581	2022, DACO 2 Report [PRIVACY INFO REMOVED] 21Dec2022, DACO: 2.1,2.11.2,2.11.3,2.11.4,2.12.1,2.13.3,2.2,2.3,2.3.1,2.5,2.6,2.7,2.8,2.9 CBI
3425583	2021, ADAMA Glufosinate Technical 5 Batch Analysis [PRIVACY INFO REMOVED], DACO: 2.13.1,2.13.2,2.13.3,2.13.4 CBI
3444409	2023, GA_[PRIVACY INFO REMOVED]_DACO_2_08Mar2023, DACO: 2.1,2.11.2,2.11.3,2.11.4,2.12.1,2.13.3,2.2,2.3,2.3.1,2.5,2.6,2.7,2.8,2.9 CBI
3444410	2022, EPP00564 (AN21061601) US Part A, DACO: 2.13.1,2.13.2,2.13.3 CBI
3444411	2022, EPP00564 (AN21061601) US Part B, DACO: 2.13.1,2.13.2,2.13.3,2.13.4 CBI
3510567	2023, [CBI REMOVED]-Glufosinate-[PRIVACY INFO REMOVED], DACO: 2.13.4 CBI
3513883	2023, NC-2023-138 Preliminary Analysis Report-final, DACO: 2.13.4 CBI

© His Majesty the King in Right of Canada, as represented by the Minister of Health Canada, 2024

All rights reserved. No part of this information (publication or product) may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in a retrieval system, without prior written permission of Health Canada, Ottawa, Ontario K1A 0K9.